NASDAQ:CFMS - ConforMIS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ConforMIS Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.05 -0.05 (-4.55 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$1.03Now: $1.05▼$1.1250-Day Range$0.96MA: $1.15▼$1.5552-Week Range$0.91Now: $1.05▼$4.83Volume857,800 shsAverage Volume657,889 shsMarket Capitalization$72.15 millionP/E RatioN/ADividend YieldN/ABeta2.27 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFMS Previous Symbol CUSIPN/A CIK1305773 Webhttp://www.conformis.com/ Phone781-345-9001Debt Debt-to-Equity Ratio1.83 Current Ratio3.11 Quick Ratio2.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$89.79 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.84Profitability EPS (Most Recent Fiscal Year)($0.74) Net Income$-43,370,000.00 Net Margins-41.36% Return on Equity-115.71% Return on Assets-49.59%Miscellaneous Employees262 Outstanding Shares68,712,000Market Cap$72.15 million Next Earnings Date3/2/2020 (Confirmed) OptionableNot Optionable Receive CFMS News and Ratings via Email Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CFMS Rates by TradingView ConforMIS (NASDAQ:CFMS) Frequently Asked Questions What is ConforMIS's stock symbol? ConforMIS trades on the NASDAQ under the ticker symbol "CFMS." How were ConforMIS's earnings last quarter? ConforMIS Inc (NASDAQ:CFMS) announced its earnings results on Wednesday, October, 30th. The medical instruments supplier reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02. The medical instruments supplier had revenue of $17.30 million for the quarter, compared to the consensus estimate of $17.80 million. ConforMIS had a negative return on equity of 115.71% and a negative net margin of 41.36%. View ConforMIS's Earnings History. When is ConforMIS's next earnings date? ConforMIS is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for ConforMIS. How can I listen to ConforMIS's earnings call? ConforMIS will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What guidance has ConforMIS issued on next quarter's earnings? ConforMIS updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.9-19.9 million, compared to the consensus revenue estimate of $20.21 million. What price target have analysts set for CFMS? 2 equities research analysts have issued 12 month price objectives for ConforMIS's shares. Their forecasts range from $3.00 to $4.00. On average, they expect ConforMIS's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for ConforMIS. What is the consensus analysts' recommendation for ConforMIS? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS. What are Wall Street analysts saying about ConforMIS stock? Here are some recent quotes from research analysts about ConforMIS stock: 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (11/4/2019) 2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019) Has ConforMIS been receiving favorable news coverage? Media headlines about CFMS stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ConforMIS earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for ConforMIS. Are investors shorting ConforMIS? ConforMIS saw a decline in short interest in January. As of January 31st, there was short interest totalling 3,060,000 shares, a decline of 13.6% from the January 15th total of 3,540,000 shares. Based on an average daily trading volume, of 551,400 shares, the days-to-cover ratio is presently 5.5 days. Approximately 4.8% of the company's stock are sold short. View ConforMIS's Current Options Chain. Who are some of ConforMIS's key competitors? Some companies that are related to ConforMIS include Invacare (IVC), Sientra (SIEN), Lakeland Industries (LAKE), Histogenics (HSGX), COLLPLANT HOLDI/S (CLGN), Bionik Laboratories (BNKL), NanoVibronix (NAOV), Precision Therapeutics (POAI), Allied Healthcare Products (AHPI), Ocugen (OCGN), Rewalk Robotics (RWLK) and Avitar (AVTI). What other stocks do shareholders of ConforMIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), NVIDIA (NVDA), Micron Technology (MU), AT&T (T), Advanced Micro Devices (AMD), Cisco Systems (CSCO), AbbVie (ABBV), Alibaba Group (BABA), Pfizer (PFE) and Intel (INTC). Who are ConforMIS's key executives? ConforMIS's management team includes the folowing people: Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)Mr. Ed Kilgallen, VP of OperationsMs. Lisa M. Donnelly, Sr. VP of Global Marketing When did ConforMIS IPO? (CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers. Who are ConforMIS's major shareholders? ConforMIS's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.22%), Archon Capital Management LLC (6.34%), Geode Capital Management LLC (2.17%), State Street Corp (2.01%), AQR Capital Management LLC (1.94%) and UBS Group AG (1.19%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, Erin Henry, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS. Which major investors are selling ConforMIS stock? CFMS stock was sold by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, AQR Capital Management LLC, Oxford Asset Management LLP, Renaissance Technologies LLC, Secrest Blakey & Associates LLC and Creative Planning. Company insiders that have sold ConforMIS company stock in the last year include Archon Capital Management Llc, Bradley Langdale, Erin Henry, Mark A Augusti, Patricia A Davis and Paul S Weiner. View Insider Buying and Selling for ConforMIS. Which major investors are buying ConforMIS stock? CFMS stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, UBS Group AG, ARK Investment Management LLC, Alambic Investment Management L.P., Goldman Sachs Group Inc., Citigroup Inc. and Barclays PLC. View Insider Buying and Selling for ConforMIS. How do I buy shares of ConforMIS? Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ConforMIS's stock price today? One share of CFMS stock can currently be purchased for approximately $1.05. How big of a company is ConforMIS? ConforMIS has a market capitalization of $72.15 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. ConforMIS employs 262 workers across the globe.View Additional Information About ConforMIS. What is ConforMIS's official website? The official website for ConforMIS is http://www.conformis.com/. How can I contact ConforMIS? ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected] MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 327 (Vote Outperform)Underperform Votes: 273 (Vote Underperform)Total Votes: 600MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: How prevalent are 12b-1 fees?
